Press release
Intravenous Immunoglobulin Market Revenue to Expand Significantly by 2032, States DelveInsight Report | Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions
The latest healthcare forecast report provides an in-depth analysis of Intravenous Immunoglobulin, offering comprehensive insights into the Intravenous Immunoglobulin revenue trends, prevalence, and treatment landscape. The report delves into key Intravenous Immunoglobulin statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Intravenous Immunoglobulin therapies. Additionally, we cover the landscape of Intravenous Immunoglobulin clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Intravenous Immunoglobulin treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Intravenous Immunoglobulin space.
To Know in detail about the Intravenous Immunoglobulin market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Intravenous Immunoglobulin Market Forecast
https://www.delveinsight.com/sample-request/intravenous-immunoglobulin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Intravenous Immunoglobulin Market Report:
• The Intravenous Immunoglobulin market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In June 2024, FDA approved YIMMUGOfromGrifols Biotestfor thetreatment of primary immunodeficiencies for 17 and above age group
• Key Intravenous Immunoglobulin Companies: Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions, and others
• Key Intravenous Immunoglobulin Therapies: TAK-880, TA-650, ABBV-383 (Etentami), IVIG-L, and others
• The Intravenous Immunoglobulin market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Intravenous Immunoglobulin pipeline products will significantly revolutionize the Intravenous Immunoglobulin market dynamics.
• As per NORD (2024), Guillain-Barré Syndrome (GBS) impacts approximately one to two individuals per 100,000 people annually.
• According to DelveInsight's analysis, the total number of prevalent Immune Thrombocytopenia (ITP) cases in the EU4 countries and the UK was approximately 91,900 in 2023.
• According to DelveInsight's analysis, the total number of prevalent cases of CIDP in Japan was estimated to be around 2,120 in 2023.
• According to Duff et al. (2021), more than 6 million individuals globally are impacted by primary immunodeficiencies, yet 70% to 90% of these cases go undiagnosed. Over 430 types of primary immunodeficiencies (PIDs) have been identified, all resulting from inherited abnormalities in various parts of the immune system.
Intravenous Immunoglobulin Overview
Intravenous Immunoglobulin (IVIG) is a therapy made from pooled antibodies (immunoglobulins) collected from the plasma of healthy donors. It is administered through a vein to help strengthen the immune system. IVIG is commonly used to treat immune deficiencies, certain autoimmune disorders, and inflammatory diseases. It works by modulating immune responses, reducing inflammation, and neutralizing harmful antibodies in the body.
Get a Free sample for the Intravenous Immunoglobulin Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/intravenous-immunoglobulin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Intravenous Immunoglobulin Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Intravenous Immunoglobulin Epidemiology Segmentation:
The Intravenous Immunoglobulin market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Intravenous Immunoglobulin
• Prevalent Cases of Intravenous Immunoglobulin by severity
• Gender-specific Prevalence of Intravenous Immunoglobulin
• Diagnosed Cases of Episodic and Chronic Intravenous Immunoglobulin
Download the report to understand which factors are driving Intravenous Immunoglobulin epidemiology trends @ Intravenous Immunoglobulin Epidemiology Forecast
https://www.delveinsight.com/sample-request/intravenous-immunoglobulin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Intravenous Immunoglobulin Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Intravenous Immunoglobulin market or expected to get launched during the study period. The analysis covers Intravenous Immunoglobulin market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Intravenous Immunoglobulin Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Intravenous Immunoglobulin Therapies and Key Companies
• TAK-880: Takeda
• TA-650: Mitsubishi Tanabe Pharma
• ABBV-383 (Etentami): AbbVie
• IVIG-L: Prothya Biosolutions
Discover more about therapies set to grab major Intravenous Immunoglobulin market share @ Intravenous Immunoglobulin Treatment Landscape
https://www.delveinsight.com/sample-request/intravenous-immunoglobulin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Intravenous Immunoglobulin Market Drivers
• Rising prevalence of immunodeficiency disorders
• Increased use of IVIG in autoimmune and neurological disorders
• Growing geriatric population
• Supportive government initiatives and reimbursement policies
• Increasing awareness and early diagnosis of rare immune disorders
• Expansion of healthcare infrastructure
Intravenous Immunoglobulin Market Barriers
• High cost of IVIG therapy
• Supply constraints and plasma shortages
• Stringent regulatory requirements
• Limited awareness in underdeveloped regions
• Competition from alternative therapies
Scope of the Intravenous Immunoglobulin Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Intravenous Immunoglobulin Companies: Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions, and others
• Key Intravenous Immunoglobulin Therapies: TAK-880, TA-650, ABBV-383 (Etentami), IVIG-L, and others
• Intravenous Immunoglobulin Therapeutic Assessment: Intravenous Immunoglobulin current marketed and Intravenous Immunoglobulin emerging therapies
• Intravenous Immunoglobulin Market Dynamics: Intravenous Immunoglobulin market drivers and Intravenous Immunoglobulin market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Intravenous Immunoglobulin Unmet Needs, KOL's views, Analyst's views, Intravenous Immunoglobulin Market Access and Reimbursement
To know more about Intravenous Immunoglobulin companies working in the treatment market, visit @ Intravenous Immunoglobulin Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/intravenous-immunoglobulin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Intravenous Immunoglobulin Market Report Introduction
2. Executive Summary for Intravenous Immunoglobulin
3. SWOT analysis of Intravenous Immunoglobulin
4. Intravenous Immunoglobulin Patient Share (%) Overview at a Glance
5. Intravenous Immunoglobulin Market Overview at a Glance
6. Intravenous Immunoglobulin Disease Background and Overview
7. Intravenous Immunoglobulin Epidemiology and Patient Population
8. Country-Specific Patient Population of Intravenous Immunoglobulin
9. Intravenous Immunoglobulin Current Treatment and Medical Practices
10. Intravenous Immunoglobulin Unmet Needs
11. Intravenous Immunoglobulin Emerging Therapies
12. Intravenous Immunoglobulin Market Outlook
13. Country-Wise Intravenous Immunoglobulin Market Analysis (2019-2032)
14. Intravenous Immunoglobulin Market Access and Reimbursement of Therapies
15. Intravenous Immunoglobulin Market Drivers
16. Intravenous Immunoglobulin Market Barriers
17. Intravenous Immunoglobulin Appendix
18. Intravenous Immunoglobulin Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Intravenous Immunoglobulin Epidemiology https://www.delveinsight.com/report-store/intravenous-immunoglobulin-ivig-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Intravenous Immunoglobulin Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Intravenous Immunoglobulin epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
• Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Intravenous Immunoglobulin Market Revenue to Expand Significantly by 2032, States DelveInsight Report | Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions here
News-ID: 4072963 • Views: …
More Releases from DelveInsight Business Research
Global Coronary Stents Market to grow at a CAGR of 7.51% by 2030, Evaluates Delv …
According to DelveInsight's analysis, the increasing demand for coronary stents is largely driven by the rising incidence of cardiovascular diseases and the growing risk factors linked to coronary artery disease. Moreover, the global surge in minimally invasive surgical procedures, combined with ongoing technological advancements in stent design, are significant contributors to the anticipated growth of the coronary stents market between 2024 and 2030.
DelveInsight's "Coronary Stents Market Insights, Competitive Landscape and…
Global Medical Tourism Market to grow at a CAGR of 11.04% by 2030, Evaluates Del …
According to DelveInsight's analysis, The growth of the medical tourism market from 2024 to 2030 is expected to be driven by several key factors, including limited insurance coverage for certain treatments in home countries, lack of support for specific medical procedures locally, and added advantages offered by destination countries such as affordable care, high-quality hospitality, personalized treatment, and increasing government efforts and partnerships to promote medical tourism.
DelveInsight's "Medical Tourism Market…
Neurotrophic Keratopathy Drugs Market 2032: Clinical Trials, EMA, PDMA, FDA Appr …
(Albany, USA) DelveInsight's "Neurotrophic Keratopathy Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Neurotrophic Keratopathy, historical and forecasted epidemiology as well as the Neurotrophic Keratopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Neurotrophic Keratopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratopathy Market Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the…
Neurotrophic Keratopathy Drugs Market 2032: Clinical Trials, EMA, PDMA, FDA Appr …
(Albany, USA) DelveInsight's "Neurotrophic Keratopathy Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Neurotrophic Keratopathy, historical and forecasted epidemiology as well as the Neurotrophic Keratopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Neurotrophic Keratopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratopathy Market Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the…
More Releases for Intravenous
Intravenous (IV) Solutions Market
The Global Intravenous (IV) Solution Market is expected to reach USD 11,511.2 million by 2022 and is expected to grow at a CAGR of 7.69% during the forecast period 2016-2022. The factors which drive the growth of the market are the rising prevalence of chronic diseases, rising acceptance of vitamin C intravenous treatment therapy to treat colorectal cancer.
Key Finding
The global Intravenous (IV) Solution market and is expected to reach USD…
Intravenous Solutions Market Opportunity Analysis, 2026
Intravenous solutions are the chemically prepared fluids, which are administered in the body through venous circulation to maintain or replace the lost body fluid level. There are various types of IV solutions that have different effects on a human body. Majority of intravenous solutions constitute of solvent and solute out of which solvents are sterile water and solutes are electrolytes such as sodium, potassium, and chloride. Intravenous solutions market is…
Intravenous Product Packaging Market -
Global healthcare sector continues to develop at an impressive rate. As a result, packaging marketplace is undergoing huge changes with specialized focus on offering innovative packaging tools/products to pharmaceutical industry. One such core product that offers lucrative market opportunities for packaging companies is intravenous products.
Download PDF Brochure For Future Advancements@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14075
Intravenous product such as catheters and IV fluid bags are mainly used to prevent and treat various chronic illness…
Intravenous Immunoglobulin (IVIg) Market Professional Survey Report
The term “immunoglobulin” refers to the breakdown of blood plasma that contains antibody. IVIg is a blood product which is administered intravenously. It contains polyvalent IgG antibodies which are extracted from the plasma of more than thousand of blood donors. Individuals who are unable to produce adequate amount of antibodies, such as patients with common variable immunodeficiency, Wiskott Aldrich Syndrome, X-linked agammaglobulinemia and other forms of hypogammaglobulinemia, get benefit from…
Peripheral Intravenous Catheter Market
New research report offers a comprehensive analysis of the “Peripheral Intravenous Catheter Market: Asia Pacific Regional Market to Witness the Fastest Growth Throughout the Forecast Period: Global Industry Analysis & Opportunity Assessment, 2016-2021“The main objective of this report is to deliver insightful information and clear-cut facts pertaining to the growth trajectories of the market.
Request to view Sample Report @ https://www.mrrse.com/sample/2827
Peripheral intravenous catheter is a sophisticated medical device widely used to…
Intravenous Immunoglobulin Market Analysis & Trends 2024
Transparency Market Research estimates that the global intravenous immunoglobulin (IVIG) market, which was valued at US$7.23 bn in 2015, is projected to expand at a CAGR of 8.5% from 2016 to 2024 and reach US$14.92 bn in 2024. In terms of end users, the hospitals segment is presently leading, accounting for a more than 62% of the overall market in 2015. The segment is, however, expected to lose prominence to…
